Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.58 |
| ▸ | AHR | P35869 | 2/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.45 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.44 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL347687 | 0.85 | LOXL2 (0.58) | LOXL2AHRHRH3HRH4MTNR1A | |
| SCHEMBL396373 | 0.81 | LOXL2 (0.58) | LOXL2AHRHRH3HRH4MTNR1A | |
| SCHEMBL29851915 | 0.81 | LOXL2 (0.58) | LOXL2AHRHRH3HRH4MTNR1A | |
| SCHEMBL30939452 | 0.81 | LOXL2 (0.58) | LOXL2AHRHRH3HRH4MTNR1A | |
| SCHEMBL5262099 | 0.81 | LOXL2 (0.58) | LOXL2AHRHRH3HRH4MTNR1A | |
| Methane SCHEMBL29165338 | 0.79 | LOXL2 (0.56) | LOXL2AHRHRH3HRH4MTNR1A | |
| SCHEMBL31230610 | 0.78 | LOXL2 (0.55) | LOXL2AHRHRH3HRH4MTNR1A | |
| SCHEMBL7169246 | 0.77 | LOXL2 (0.69) | LOXL2AHRHRH3HRH4MTNR1A | |
| SCHEMBL31059889 | 0.77 | LOXL2 (0.69) | LOXL2AHRHRH3HRH4MTNR1A | |
| SCHEMBL401081 | 0.77 | LOXL2 (0.69) | LOXL2AHRHRH3HRH4MTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8450525-B2 | Histone deacetylase inhibitors | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2013-05-28 | — | — | US | claimed |
| US-20100298402-A1 | STILBENE DERIVATIVES AS PSTAT3/IL-6 INHIBITORS | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2010-11-25 | — | — | US | claimed |
| US-20100291003-A1 | HISTONE DEACETYLASE INHIBITORS | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2010-11-18 | — | — | US | claimed |
| EP-2209765-A2 | HISTONE DEACETYLASE INHIBITORS | Orchid Research Laboratories Limited (IN) | 2010-07-28 | — | — | EP | claimed |
| WO-2009060282-A2 | STILBENE DERIVATIVES AS PSTAT3/IL-6 INHIBITORS | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2009-05-14 | — | — | WO | claimed |
| WO-2009053808-A2 | HISTONE DEACETYLASE INHIBITORS | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2009-04-30 | — | — | WO | claimed |
| US-8053598-B2 | Compounds, their preparation and use | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-11-08 | — | — | US | disclosed |
| EP-1745014-B1 | NOVEL COMPOUNDS, THEIR PREPARATION AND USE | HIGH POINT PHARMACEUTICALS LLC (US) | 2011-07-06 | — | — | EP | disclosed |
| US-20090012171-A1 | Novel Compounds, Their Preparation and Use | NOVO NORDISK A/S (CZ) | 2009-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100291003-A1 | HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC11, HDAC5 | LOXL2 3500/4885AHR 402/4885HRH3 457/4885 |
| US-20100298402-A1 | STILBENE DERIVATIVES AS PSTAT3/IL-6 INHIBITORS | IL6, IL6ST, STAT3 | LOXL2 3001/4885AHR 1967/4885HRH3 4037/4885 |
| US-20090012171-A1 | Novel Compounds, Their Preparation and Use | PPARG, PPARD, PPARA | LOXL2 2679/4885AHR 1215/4885HRH3 2760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.